EP2077900A2 - Procédés et systèmes d'immobilisation des prothèses de cornée - Google Patents

Procédés et systèmes d'immobilisation des prothèses de cornée

Info

Publication number
EP2077900A2
EP2077900A2 EP07854490A EP07854490A EP2077900A2 EP 2077900 A2 EP2077900 A2 EP 2077900A2 EP 07854490 A EP07854490 A EP 07854490A EP 07854490 A EP07854490 A EP 07854490A EP 2077900 A2 EP2077900 A2 EP 2077900A2
Authority
EP
European Patent Office
Prior art keywords
prosthesis
growth factor
corneal
reactive
cornea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07854490A
Other languages
German (de)
English (en)
Inventor
Yichieh Shiuey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP2077900A2 publication Critical patent/EP2077900A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • A61F2/142—Cornea, e.g. artificial corneae, keratoprostheses or corneal implants for repair of defective corneal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea

Definitions

  • Corneal onlays are corneal prostheses placed on
  • Corneal implants are corneal prostheses which are placed within the corneal stroma e.g. below the level of Bowman's membrane.
  • a significant problem with existing designs for corneal onlays and corneal implants is that there currently are not any good methods to attach these prostheses to the cornea.
  • Sutures are unsatisfactory because they may cause damage to the prosthesis and distort the shape of the prosthesis. Any distortion of the prosthesis may result in degradation of its optical properties. Sutures also take considerable time and skill to place. Adhesives e.g. glues are also unsatisfactory because they are difficult to apply to the cornea in an even and smooth fashion. Adhesives tend to flow irregularly, and the volume of adhesive applied is difficult to control at the microscopic level. Lack of evenness or smoothness underneath or around the corneal prosthesis may distort the shape of the prosthesis and degrade its optical properties.
  • the present invention provides improved corneal prostheses and methods for immobilizing such prostheses on a cornea.
  • the prostheses may be any type of prosthesis, such as an onlay or an implant, having a polymeric body with corrective optical properties or cosmetic properties.
  • the present invention relies on modifying at least one of a posterior surface and/or an anterior surface of the prosthesis.
  • the posterior surface may be modified to promote covalent attachment to the corneal tissue.
  • the anterior surface may be modified to promote epathelialization. The surface modifications will have little or no effect on the corrective optical properties of the prosthesis either before or after implantation.
  • a method for immobilizing a corneal prosthesis on a cornea comprises positioning the corneal prosthesis in contact with corneal tissue. At least a portion of an interior surface of the prosthesis displays a "native" cross- linking biomolecule such that, by irradiating the corneal prosthesis with energy under conditions selected to cross-link the native biomolecule with endogenous moieties in the corneal tissue, the prosthesis is immobilized on the tissue. Both the concentration of cross- linking molecule introduced and the conditions of irradiation are selected so that the prosthesis will remain in place without significant displacement during all normal patient conditions and activities. The bonding, however, will not be so strong that the prosthesis cannot be removed by peeling or other intentional removal step.
  • the prosthesis body will typically be composed of an optical polymer, which at least partially contains one or more compounds selected from the group consisting of collagen, polyurethanes, poly(2-hydroxyethylmethacrylate), polyvinylpyrolidone, polyglycerolmethacrylate, polyvinyl alcohol, polyethylene glycol, polymethacrylic acid, silicones, polyfluorocarbons, N-isopropylacrylamide, l-ethyl-3,3' (dimethyl- aminopropyl)carbodidimide, N-hydroxysuccinimidepolymers with phosphocholine [0008] Another group of polymers which may be appropriate for the manufacture of the prosthesis body consists of polysiloxanes, perfluoroalkyl polyethers, fluorinated poly(meth)acrylates or equivalent fluorinated polymers derived e.g.
  • polymerizable carboxylic acids from other polymerizable carboxylic acids, polyalkyl (meth)acrylates or equivalent alkylester polymers derived from other polymerizable carboxylic acids, polyolefines, or fluorinated polyolefines, such as polyvinylidene fluoride, fluorinated ethylene propylene, or tetrafluoroethylene, preferably in combination with specific dioxols, such as perfluoro-2,2-dimethyl-l ,3-dioxol.
  • suitable bulk materials are e.g.
  • Teflon AF materials such as Teflon AF 1600 or Teflon AF 2400 which are copolymers of about 63 to 73 mol % of perfluoro-2,2-dimethyl-l ,3-dioxol and about 37 to 27 mol % of tetrafluoroethylene, or of about 80 to 90 mol % of perfluoro-2,2-dimethyl-l ,3-dioxol and about 20 to 10 mol % of tetrafluoroethylene.
  • a group of particularly preferred hydrophobic polymers are non-porous or particularly porous perfluoroalkyl polyether (PFPE) homo- or copolymers or perfluoroalkyl acrylates or methacrylates, for example those as disclosed in PCT applications WO 96/31546, WO 96/31548, WO 97/35906 or WO 00/15686.
  • PFPE perfluoroalkyl polyether
  • Another preferred group of polymers suitable for manufacture of the prosthesis body consists of those being conventionally used for the manufacture of biomedical devices, e.g. contact lenses, which are hydrophilic per se, since hydrophilic groups, e.g. carboxy, carbamoyl, sulfate, sulfonate, phosphate, amine, ammonium or hydroxy groups, are inherently present in the material.
  • hydrophilic groups e.g. carboxy, carbamoyl, sulfate, sulfonate, phosphate, amine, ammonium or hydroxy groups
  • Such materials are known to the skilled artisan and comprise for example polyhydroxyethyl acrylate, polyhydroxyethyl methacrylate (HEMA), polyvinyl pyrrolidone (PVP), polyacrylic acid, polymethacrylic acid, polyacrylamide, poly- N,N-dimethyl acrylamide (DMA), polyvinyl alcohol, copolymers for example from two or more monomers from the group hydroxyethyl acrylate, hydroxyethyl methacrylate, N-vinyl pyrrolidone, acrylic acid, methacrylic acid, acrylamide, N,N-dimethyl acrylamide, vinyl alcohol, vinyl acetate and the like, polyalkylene glycols such as polyethylene glycols, polypropylene glycols or polyethylene/polypropylene glycol block copolymers.
  • HEMA polyhydroxyethyl methacrylate
  • PVP polyvinyl pyrrolidone
  • polyacrylic acid polymethacrylic acid
  • Typical examples are e.g. Polymacon, Tefilcon, Methaf ⁇ lcon, Deltafilcon, Buf ⁇ lcon, Phemf ⁇ lcon, Ocuf ⁇ lcon, Focofilcon, Etafilcon, Hefilcon, Vifilcon, Tetrafilcon, Perfilcon, Droxifilcon, Dimefilcon, Isofilcon, Mafilcon, Nelf ⁇ lcon or Atlafilcon.
  • Another group of preferred polymers for the prosthesis body consists of amphiphilic segmented copolymers comprising at least one hydrophobic segment and at least one hydrophilic segment which are linked through a direct bond or a bridge member.
  • amphiphilic segmented copolymers comprising at least one hydrophobic segment and at least one hydrophilic segment which are linked through a direct bond or a bridge member.
  • silicone hydrogels for example those disclosed in PCT applications WO 96/31792 and WO 97/49740.
  • the native cross-linking biomolecule will usually comprise a human protein or polypeptide but could also include other biomolecules such as carbohydrates and small molecules.
  • Exemplary cross-linking biomolecules include proteins selected from the group consisting of collagen, fibronectin, laminin, kalinin, K-laminin, vitronectin, talin, integrin, albumin, insulin-like growth factor, fibroblast growth factor, hepatocyte growth factor, epithelial growth factor, transforming growth factor- ⁇ ., transforming growth factor- ⁇ , keratinocyte growth factor, heparin binding factor, fibroblast growth factor, nerve growth factor, substance P, interleukin-1 ⁇ , and interleukin-1 ⁇ , polypeptides selected from the group consisting of FAP, YIGSR, SIYITRF, PHSRN, IAFQRN, and LQVQLSIR; and small molecules selected from the group consisting of 1 ,8 naphthalimide, diazopyruvate, diazopyruvamide
  • the general formula is RHNCOCOCHN2 where R is a tethering molecule selected from the group consisting of oligopeptides, polypeptides, and polyethylene glycol.
  • the diazopyruvate is 4-nitrophenyl-3 -diazopyruvate.
  • the irradiation step may optionally be performed in the presence of a non-toxic catalyst which is selected to promote cross-linking, such as riboflavin, rose Bengal or glucose.
  • a non-toxic catalyst which is selected to promote cross-linking, such as riboflavin, rose Bengal or glucose.
  • at least a portion of the posterior side of the prosthesis may display a tissue growth promotant in order to promote tissue growth adjacent to the prosthesis after placement and implantation.
  • corneal prostheses comprise a polymeric body having corrective optical properties. At least a portion of an anterior surface of the optical body displays native biomolecules, as described above, which cross-link with endogenous corneal moieties in the corneal tissue when exposed to ultraviolet or other selected radiation.
  • the prosthesis will typically be an onlay or an implant, and the prosthesis body will be typically at least partially contains one or more compounds selected from the group consisting of collagen, polyurethanes, poly(2-hydroxyethylmethacrylate), polyvinylpyrolidone, polyglycerolmethacrylate, polyvinyl alcohol, polyethylene glycol, polymethacrylic acid, silicones, polyfluorocarbons,N-isopropylacrylamide, l-ethyl-3,3' (dimethyl-aminopropyl)carbodidimide, N-hydroxysuccinimide and polymers with phosphocholine.
  • collagen polyurethanes
  • poly(2-hydroxyethylmethacrylate) polyvinylpyrolidone
  • polyglycerolmethacrylate polyvinyl alcohol
  • polyethylene glycol polymethacrylic acid
  • silicones polyfluorocarbons
  • Figure 1 schematically illustrates attachment of a prosthesis to a cornea in accordance with the principles of the present invention.
  • Figure 2 illustrates a bonding reaction between a PHEMA/MAA prosthesis derivatized with diazopyruvamide and corneal collagen.
  • Figures 3A and 3B illustrate an apparatus suitable for performing the methods of Figure 1.
  • Figure 4 is a schematic illustration of a corneal prosthesis intended for treating presbyopia.
  • Corneal prostheses e.g. implants or onlays
  • Corneal prostheses are modified to contain naturally occurring non-toxic proteins, peptides, amino acids or amino acid derivatives or other small molecules capable of becoming chemically bonded to endogenous molecules in the cornea through exposure to irradiation.
  • the resulting chemical bonds will be sufficiently strong to immobilize the prosthesis, that is hold the prosthesis in place, on the cornea under normal patient conditions and activities but may be broken by either physical force or by exposure to solvents to allow removal of the corneal prosthesis in the event that the corneal prosthesis needs to be removed.
  • the corneal prosthesis is surface modified (attached) with a native biomolecule or derivative thereof, usually mammalian, most usually human extracellular matrix proteins e.g. collagen, fibronectin, laminin, peptide fragments of extracellular matrix proteins e.g. fibronectin adhesion-promoting peptide sequence (FAP), or a diazopyruvate (e.g. 4-nitrophenyl-3-diazopyruvate).
  • FAP fibronectin adhesion-promoting peptide sequence
  • diazopyruvate e.g. 4-nitrophenyl-3-diazopyruvate
  • the native biomolecule is attached to the corneal prosthesis by a nontoxic spacer molecule (e.g. polyethylene glycol, an olgiopeptide or a polypeptide).
  • the corneal prosthesis may be formed from a polymer which contains native biomolecules within the polymer e.g. collagen, fibronectin, laminin, peptide fragments of extracellular matrix proteins, a diazopyruvate or a diazopyruvamide.
  • Fixation of a corneal onlay on the cornea may be initiated, for example, by irradiation, particularly by irradiation with ultraviolet or visible light.
  • the cornea is previously prepared for the attachment of the onlay, for example by removing the epithelial cell layers of the cornea by scraping.
  • the onlay is placed in intimate contact with the corneal tissue and is then irradiated.
  • Suitable light sources for the irradiation are known to the artisan and comprise for example mercury lamps, high pressure mercury lamps, xenon lamps, carbon arc lamps or sunlight.
  • Sensitizers may be used to shift the irradiation wavelength.
  • a suitable filter may be used to limit the irradiation to a specific wavelength range.
  • the onlay surface to which have been previously applied the native biomolecules is irradiated with light of a wavelength 300 nm, preferably from 350 to 400 nm.
  • the time period of irradiation is not critical but is usually in the range of up to 30 minutes, preferably from 10 seconds to 10 minutes, and more preferably from 15 seconds to 5 minutes, and particularly preferably from 20 seconds to 1 minute.
  • One preferred method of implanting a corneal onlay onto a cornea thus comprises (i) providing a surface modified onlay with modification at its posterior surface only; (ii) placing the onlay in contact with the corneal tissue (usually after de-epithelialization as described above); and (iii) irradiating the onlay whereby the onlay is fixed on the cornea.
  • irradiation is limited to the area of the onlay so that exposure of the cornea is minimized.
  • the anterior surface of the implant may be coated with a tissue growth promoting compound as described hereinafter.
  • the anterior surface of the onlay may have been surface modified with tissue growth promoting compounds to promote epithelialization prior to the fixation step.
  • a preferred method of implanting a corneal prosthesis within a cornea comprises (i) providing a surface modified implant which has been modified at both its posterior and anterior surface, (ii) placing the implant in contact with the corneal tissue; (iii) before or after step (ii) coating the anterior surface with one or more components which promote the growth of tissue adjacent to the implanted onlay, and (iv) irradiating the onlay whereby the implant is fixed within the corneal tissues and the tissue growth promoting compound is fixed on the anterior onlay surface.
  • the anterior surface of the implant may have been surface modified with tissue growth promoting compounds to promote epithelialization prior to the fixation step.
  • Suitable tissue growth promoting compounds in both above mentioned methods are, for example, albumins, extracellular matrix (ECM) proteins, fibronectin, laminin, chondroitan sulfate, collagen, cell-attachment proteins, anti-gelatine factor, cold-insoluble globulin, chondronectin, epidermal growth factor, mussel adhesive protein, sialo proteins, thrombospondin, vitronectin, and various proteoglycans, and/or derivatives of the above or mixtures thereof.
  • ECM extracellular matrix
  • tissue growth promoting compounds are kalinin, K- laminin, vitronectin, talin, integrin, albumin, insulin-like growth factor, fibroblast growth factor, hepatocyte growth factor, epithelial growth factor, transforming growth factor-. alpha., transforming growth factor- .beta., keratinocyte growth factor, heparin binding factor, fibroblast growth factor, nerve growth factor, substance P; interleukin-1 alpha, interleukin-1 beta, FAP, YIGSR, SIYITRF, PHSRN, IAFQRN, and LQVQLSIR
  • the above described corneal prosthesis is chemically bonded to the cornea by irradiation with ultraviolet or visible light at a 1 -cm or less distance for up to 30 minutes.
  • a non-toxic catalyst such as riboflavin, rose bengal, or glucose may be used to facilitate the chemical bonding.
  • the exposure of the electromagnetic waves to the prosthesis may either be completely over the prosthesis or only partly over the prosthesis. Partial exposure of the corneal prosthesis to electromagnetic waves may be all that is necessary to secure the prosthesis to the cornea and advantageously decreases exposure of the eye to electromagnetic energy.
  • the corneal prosthesis may be a lens which has a corrective optical property, such as correcting refractive errors such as myopia, hyperopia, astigmatism, or higher order aberrations.
  • the corneal prosthesis may also be multifocal to allow treatment of refractive errors as well as presbyopia.
  • the corneal prosthesis corrects the refractive error by changing the curvature of the corneal tear film, by modifying the net refractive index of the cornea, or a combination of both.
  • the average power of the cornea after implantation or attachment of the prosthesis will in preferred aspects be between 25 and 55 diopters.
  • the shape of the corneal prosthesis which is necessary for vision correction may be achieved by molding, laser ablation, or a combination of both. In the case of laser ablation, ablation may be performed to the prosthesis prior to fixation to the eye or subsequent to fixation to the eye
  • the corneal prosthesis may have a superior area which has a curvature and/or refractive index which will give the superior cornea an effective refraction between -1.0 and -4.0 diopters.
  • the corneal prosthesis may also have an inferior area which has a curvature and/or refractive index which will give the inferior cornea an effective refraction between 0 and -1.0 diopters.
  • there may be a transition zone between the superior and inferior parts of the corneal prosthesis which has a gradually changing refraction which is between the refraction powers of the superior and inferior aspects of the prosthesis.
  • the optical zone of this type of presbyopia correcting prosthesis will be between 4 and 9 mm.
  • the corneal prosthesis may treat presbyopia by having a central optical zone of one optical power and at least one concentric zone of a different optical power to allow for correction of both distance vision and near vision.
  • the central optical zone may have an optical power to provide clear distance vision or clear near vision.
  • at least part of one of the concentric zone(s) would be within the pupil, usually meaning that at least part of the concentric zones(s) would be within a 2 mm radius of the center of the central optical zone.
  • the corneal prosthesis may be aspheric in design and have a gradually changing curvature , instead of discrete optical zones, which allow the focus of light from both distant and near objects.
  • the curvature at the center of the prosthesis may provide an optical power to provide either clear distance vision or clear near vision.
  • the corneal prosthesis may be colored. This advantageously allows either a permanent or reversible change in the cosmetic appearance of the eyes.
  • coloration of the prosthesis may be used to create an artificial iris for cosmetic purposes as well as to treat medical conditions such as traumatic or congenital aniridia.
  • coloration of the corneal prosthesis is achieved by the presence of a color additive on the surface of the corneal prosthesis or sealed within the corneal prosthesis.
  • color additives may consist of one or more of the following: 1 ,4- Bis[(2-hydroxy-ethyl)amino]-9,10-anthracenedione bis(2-propenoic)ester copolymers, 1 ,4- Bis [(2-methylphenyl)amino] -9,10-anthracenedione, 1,4-Bis[4- (2-methacryloxyethyl) phenylamino] anthraquinone copolymers, Carbazole violet, Chromium-cobalt-aluminum oxide, Chromium oxide greens (CI.
  • Vat Orange 2-[(2,5-Diethoxy- 4-[(4-methylphenyl)thiol] phenyl)azo] -1 ,3,5-benzenetriol, C.I. Vat brown 1 : 16,23-Dihydrodinaphtho [2,3-a:2',3'-i] naphth [2',3':6,7] indolo [2,3-c] carbazole- 5,10,15,17,22,24-hexone, C.I. Vat yellow 3: N 5 N 1 - (9,10-Dihydro- 9,10-dioxo- 1 ,5-anthracenediyl) bisbenzamide, C.I. Vat blue 6: 7,16- Dichloro- 6,15-dihydro- 5,9,14,18-anthrazinetetrone, C.I. Vat green 1 : 16,17-
  • Solvent Yellow 18 4-[(2,4-dimethylphenyl)azo]- 2,4-dihydro- 5- methyl-2-phenyl- 3H-pyrazol-3-one, C.I. Vat orange 5: 6-Ethoxy-2- (6-ethoxy-3-oxobenzo(b) thien-2(3H)- ylidene) benzo(b)thiophen- 3(2H)-one, Phthalocyanine green, Iron oxides, Titanium dioxide, Vinyl alcohol/methyl methacrylate-dye reaction products C.I. Reactive red 180, C.I. Reactive black 5, C.I. Reactive orange 78, C.I. Reactive yellow 15, C.I. Reactive blue 19, C.I. Reactive blue 21), Mica-based pearlescent pigments, (Phthalocyaninato(2-)) copper, D&C Green No. 6, D&C Red No. 17, D&C Violet No. 2, and D&C Yellow No. 10.
  • the corneal prosthesis will have a diameter between 1 and 14 mm. More preferably, the corneal prosthesis will have a diameter between 4 mm and 12.5 mm to allow an adequate sized optical zone and/or allow complete coverage of the natural iris. For treatment of presbyopia, a smaller corneal prosthesis between 1 to 4 mm, which is located at least partially in the pupil, may be preferable to create a multifocal effect.
  • the thickness of the onlay should be between 5 microns and 150 microns to allow the correction of a wide range of refractive errors The thickness of the prosthesis is not uniform throughout the onlay and preferably tapers to a thickness of 20 microns or less in the periphery of the prosthesis.
  • the thinner periphery of a prosthesis may allow easier growth of epithelium over an onlay and will decrease the empty space between the prosthesis and the corneal stroma in the case of an implant. Less empty space within the corneal stroma, advantageously decreases the likelihood of biologic debris and deposits forming around the implant.
  • the corneal prosthesis may also contain one or more holes or perforations within it to increase the depth of focus of the cornea and to provide a path for nutrients and oxygen.
  • these holes would be from 1 mm to 4 mm in its largest dimension for the purposes of increasing the depth of field .
  • the holes would typically be between 0.01 mm and .9 mm in size for the purposes of increasing the flow of nutrients and oxygen.
  • the holes or perforations may be round or not round in shape. These holes or perforations may be distributed in the center of the corneal prosthesis, in the periphery of the prosthesis or both.
  • Figure 1 shows a corneal prosthesis P of the present invention in relation to cornea C.
  • Chemical groups 10, which are found on the surfaces of corneal prosthesis P and cornea C may bond to each other in the presence of electromagnetic energy E, which in this case is ultraviolet light.
  • E electromagnetic energy
  • the chemical groups 10 do not need to be of the same type.
  • the chemical groups 10 could represent a diazopyruvamide and lysine.
  • a nontoxic catalyst (polymerization initiator) such as riboflavin or rose bengal may be used to facilitate bonding of the chemical groups.
  • the corneal prosthesis P is physically attached to cornea C by the chemical bonds 20 which are formed in the presence of ultraviolet or visible light.
  • Figure 1 shows the attachment of an onlay to the cornea, above Bowman's membrane, the same method could be used to attach a corneal implant within the cornea below the level of Bowman's membrane.
  • Figure 2 illustrates the chemical reactions involved in attaching a prosthesis made of poly(2-hydroxyethylmethacrylate)-methacrylic acid (PHEMA/MAA) to a molecule of diazopyruvamide by a PEG tether.
  • PHEMA/MAA poly(2-hydroxyethylmethacrylate)-methacrylic acid
  • the diazopyruvamide undergoes a Wolff rearrangement and loses its terminal nitrogen thereby forming a reactive ketene.
  • the reactive ketene of the diazopyruvamide then forms a covalent bond with the primary amine group of lysine or hydroxylysine on corneal collagen.
  • a prosthesis made of PHEMA/MAA or some other optical polymer can be securely attached to the cornea. Note that in this example, no catalyst is necessary to complete the attachment process.
  • Figure 3 A shows a system 100 for attaching a corneal prosthesis P to the cornea C without the use of sutures.
  • a generator 30 for electromagnetic (EM) energy typically ultraviolet, generates electromagnetic energy which is conveyed to the prosthesis P and cornea C by fiberoptic cable 40.
  • a handpiece 50 which is shown in side profile, allows the surgeon to easily control where the electromagnetic energy is directed. Handpiece 50 includes an energy applicator surface 55 from which the electromagnetic energy radiates.
  • FIG. 3B shows a bottom view of the handpiece 50 and energy applicator surface 55.
  • the energy transmitter 55 has a ring shape and that the energy is transmitted from the handpiece 50 only along the area shown in dashed lines in a ring fashion.
  • This ring configuration advantageously limits the exposure of electromagnetic energy to the periphery of the prosthesis P (not shown) and cornea C (not shown), while still allowing firm attachment of the prosthesis.
  • the drawing shows the energy transmitter in a ring configuration, any configuration or shape may also be used, including a shape which completely covers the cornea.
  • the largest dimension of the energy transmitter would be between 1 and 14 mm, more preferably between 4 and 12 mm to enable fixation of corneal prosthesis of different sizes..
  • FIG 4 shows a schematic view of a corneal prosthesis which is used for the treatment of presbyopia.
  • the superior aspect of the prosthesis 60 has a superior area which has a curvature and/or refractive index which will give the superior cornea an effective refraction between -1.0 and -4.0 diopters to provide for near vision.
  • the middle of the prosthesis 70 has a transition zone with a gradual change in refraction between the powers of 0 and -1.
  • the inferior aspect of the prosthesis 80 will also have an inferior area which has a curvature and/or refractive index which will give the inferior cornea an effective refraction between 0 and -1.0.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Surgery (AREA)
  • Epidemiology (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne les prothèses de cornée, comme les greffes apposées et les implants, ayant une surface présentant une biomolécule d'origine capable de réticulation avec les groupements endogènes dans le tissu de la cornée. Une fois mises en place, de telles prothèses peuvent être immobilisées par exposition aux ultraviolets ou autres irradiations pour réticuler les biomolécules avec les groupements endogènes.
EP07854490A 2006-10-30 2007-10-29 Procédés et systèmes d'immobilisation des prothèses de cornée Withdrawn EP2077900A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86343006P 2006-10-30 2006-10-30
PCT/US2007/082880 WO2008055118A2 (fr) 2006-10-30 2007-10-29 Procédés et systèmes d'immobilisation des prothèses de cornée

Publications (1)

Publication Number Publication Date
EP2077900A2 true EP2077900A2 (fr) 2009-07-15

Family

ID=39345028

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07854490A Withdrawn EP2077900A2 (fr) 2006-10-30 2007-10-29 Procédés et systèmes d'immobilisation des prothèses de cornée

Country Status (4)

Country Link
EP (1) EP2077900A2 (fr)
JP (1) JP2010508092A (fr)
CN (1) CN101636197A (fr)
WO (1) WO2008055118A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10729716B2 (en) 2012-03-29 2020-08-04 Cxl Ophthalmics, Llc Compositions and methods for treating or preventing diseases associated with oxidative stress
US11033429B2 (en) 2010-09-30 2021-06-15 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
US11931291B2 (en) 2012-03-29 2024-03-19 Epion Therapeutics, Inc. Ophthalmic treatment solution delivery devices and delivery augmentation methods

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8109997B2 (en) * 2009-01-18 2012-02-07 Eyeon Medical Ltd. Hydrophobic pseudo-endothelial implants for treating corneal edema
ES2704162T3 (es) 2010-09-30 2019-03-14 Keramed Inc Córnea artificial deformable reversible
WO2013148895A1 (fr) 2012-03-29 2013-10-03 Cxl Ophthalmics, Llc Système de réticulation oculaire et procédé de scellement étanche de plaies cornéennes
CN108378984B (zh) * 2013-06-25 2020-06-26 Tec晶体有限责任公司 用于眼睛的光线疗法的装置
US11259914B2 (en) 2014-05-12 2022-03-01 Gholam A. Peyman Molding or 3-D printing of a synthetic refractive corneal lenslet
US10881503B2 (en) 2014-05-12 2021-01-05 Gholam A. Peyman Method of corneal transplantation or corneal inlay implantation with cross-linking
US10925889B2 (en) 2014-05-12 2021-02-23 Gholam A. Peyman Method of treating, reducing, or alleviating a medical condition in a patient
US9937033B1 (en) * 2014-05-12 2018-04-10 Gholam A. Peyman Corneal lenslet implantation with a cross-linked cornea
US11045352B2 (en) 2014-05-12 2021-06-29 Gholam A. Peyman Methods for treatment of dry eye and other acute or chronic inflammatory processes
US11666777B2 (en) 2014-05-12 2023-06-06 Gholam A. Peyman Photodynamic therapy technique for preventing damage to the fovea of the eye or another body portion of a patient
US10195081B1 (en) 2014-05-12 2019-02-05 Gholam A. Peyman Method of prevention of capsular opacification and fibrosis after cataract extraction and/or prevention of fibrosis around a shunt or stent after glaucoma surgery
US10206569B1 (en) 2014-05-12 2019-02-19 Gholam A. Peyman Corneal intraocular pressure sensor and a surgical method using the same
US10709546B2 (en) 2014-05-12 2020-07-14 Gholam A. Peyman Intracorneal lens implantation with a cross-linked cornea
US11565023B2 (en) 2014-05-12 2023-01-31 Gholam A. Peyman Method of corneal transplantation or corneal inlay implantation with cross-linking
US11338059B2 (en) 2014-05-12 2022-05-24 Gholam A. Peyman Method of corneal and scleral inlay crosslinking and preservation
US10583221B2 (en) 2014-05-12 2020-03-10 Gholam A. Peyman Method of corneal transplantation or corneal inlay implantation with cross-linking
US11648261B2 (en) 2014-05-12 2023-05-16 Gholam A. Peyman Method of treating, reducing, or alleviating a medical condition in a patient
US10278920B1 (en) 2014-05-12 2019-05-07 Gholam A. Peyman Drug delivery implant and a method using the same
US10314690B1 (en) 2014-05-12 2019-06-11 Gholam A. Peyman Method of corneal transplantation or corneal inlay implantation with cross-linking
EP3067015B1 (fr) * 2015-03-10 2018-06-06 Consejo Superior De Investigaciones Científicas Engagement photochimiquement induit d'implants intraoculaires
WO2016201447A1 (fr) * 2015-06-12 2016-12-15 The General Hospital Corporation Produits de remplissage cornéen pour la correction d'une amétropie
DE102016110005A1 (de) 2016-05-31 2017-11-30 Universität Zu Lübeck Vorrichtung zur Brechkraftänderung der Cornea
WO2018211311A1 (fr) * 2017-05-17 2018-11-22 ANDERSON, David Warwick Procédé d'isolement de collagène
WO2019167040A1 (fr) * 2018-03-01 2019-09-06 Bar Ilan University Système, procédé et composition de matière destinés à être utilisés dans la correction de problèmes oculaires
US11529230B2 (en) 2019-04-05 2022-12-20 Amo Groningen B.V. Systems and methods for correcting power of an intraocular lens using refractive index writing
US11564839B2 (en) 2019-04-05 2023-01-31 Amo Groningen B.V. Systems and methods for vergence matching of an intraocular lens with refractive index writing
US11678975B2 (en) 2019-04-05 2023-06-20 Amo Groningen B.V. Systems and methods for treating ocular disease with an intraocular lens and refractive index writing
US11583389B2 (en) 2019-04-05 2023-02-21 Amo Groningen B.V. Systems and methods for correcting photic phenomenon from an intraocular lens and using refractive index writing
US11583388B2 (en) 2019-04-05 2023-02-21 Amo Groningen B.V. Systems and methods for spectacle independence using refractive index writing with an intraocular lens
US11944574B2 (en) 2019-04-05 2024-04-02 Amo Groningen B.V. Systems and methods for multiple layer intraocular lens and using refractive index writing
US11707518B2 (en) 2019-04-28 2023-07-25 Gholam A. Peyman Method of treating, reducing, or alleviating a medical condition in a patient
CN111840651B (zh) * 2019-04-30 2023-03-14 广东博与再生医学有限公司 一种可快速修复受损组织的角膜移植材料及其制备方法
CN111330081B (zh) * 2020-05-09 2022-03-29 山东省眼科研究所 一种载药羊膜的制备方法及其对角膜上皮修复的影响
US20240123120A1 (en) * 2022-07-13 2024-04-18 Eye Institute Of Shandong First Medical University High-adhesion artificial corneal endothelial sheet, preparation method and use thereof
WO2024077302A2 (fr) * 2022-10-07 2024-04-11 The Trustees Of Columbia University In The City Of New York Procédés de réticulation de tissu collagène

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219895A (en) * 1991-01-29 1993-06-15 Autogenesis Technologies, Inc. Collagen-based adhesives and sealants and methods of preparation and use thereof
US5836313A (en) * 1993-02-08 1998-11-17 Massachusetts Institute Of Technology Methods for making composite hydrogels for corneal prostheses
US6161544A (en) * 1998-01-28 2000-12-19 Keratoform, Inc. Methods for accelerated orthokeratology
US6827440B2 (en) * 2000-01-03 2004-12-07 Wesley Jessen Company Colored contact lens with a more natural appearance
AR030341A1 (es) * 2000-08-14 2003-08-20 Novartis Ag Articulos biomedicos moldeados
US7060288B2 (en) * 2001-02-28 2006-06-13 Timothy Charles Hughes Biomedical devices
AU2003270593A1 (en) * 2002-09-13 2004-04-30 Ocular Sciences, Inc. Devices and methods for improving vision
US20060173539A1 (en) * 2005-01-31 2006-08-03 Yichieh Shiuey Corneal implants and methods and systems for placement

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008055118A3 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11033429B2 (en) 2010-09-30 2021-06-15 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
US11135090B2 (en) 2010-09-30 2021-10-05 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
US10729716B2 (en) 2012-03-29 2020-08-04 Cxl Ophthalmics, Llc Compositions and methods for treating or preventing diseases associated with oxidative stress
US11497766B2 (en) 2012-03-29 2022-11-15 Cxl Ophthalmics, Llc Compositions and methods for treating or preventing diseases associated with oxidative stress
US11931291B2 (en) 2012-03-29 2024-03-19 Epion Therapeutics, Inc. Ophthalmic treatment solution delivery devices and delivery augmentation methods

Also Published As

Publication number Publication date
WO2008055118A2 (fr) 2008-05-08
CN101636197A (zh) 2010-01-27
JP2010508092A (ja) 2010-03-18
WO2008055118A3 (fr) 2008-10-09

Similar Documents

Publication Publication Date Title
WO2008055118A2 (fr) Procédés et systèmes d'immobilisation des prothèses de cornée
US7828844B2 (en) Inserting lenses into corneal epithelial pockets to improve vision
AU666501B2 (en) Corneal inlay lenses smaller than the optic zone
US7585075B2 (en) Corneal onlays and wavefront aberration correction to enhance vision
US9999497B2 (en) Corneal implants and methods and systems for placement
US20070182920A1 (en) Corneal Onlays and Related Methods
US20060287721A1 (en) Artificial cornea
JP6817216B2 (ja) 眼内インプラントの光化学的誘発係合
Legeais et al. A second generation of artificial cornea (Biokpro II)
US20110160851A1 (en) Keratoprosthesis
US9937033B1 (en) Corneal lenslet implantation with a cross-linked cornea
MXPA05004067A (es) Incrustacion ajustable con polimerizacion en multiples zonas.
JP2001513360A (ja) 角膜内回折性レンズ
US10709546B2 (en) Intracorneal lens implantation with a cross-linked cornea
Lane et al. Polysulfone intracorneal lenses
US9744029B1 (en) Method of preventing capsular opacification and fibrosis utilizing an accommodative intraocular lens implant
Tripti et al. Materials for intraocular lenses (IOLs): Review of developments to achieve biocompatibility
Mallen 7.6 OPHTHALMOLOGIC APPLICATIONS 329
Mallen 7.6 OPHTHALMOLOGIC APPLICATIONS 329
Bhat et al. Biomaterials in Ophthalmology
Lund SESSION IV: NEW DEVELOPMENTS II
Wnek et al. Corneal Implants/Traian V. Chirila, Celia R. Hicks

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090511

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20120127